{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:07:33Z","timestamp":1759565253871},"reference-count":28,"publisher":"Pharmaceutical Society of Japan","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2017]]},"DOI":"10.1248\/bpb.b17-00008","type":"journal-article","created":{"date-parts":[[2017,7,31]],"date-time":"2017-07-31T18:14:27Z","timestamp":1501524867000},"page":"1226-1231","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetic\/Pharmacodynamic Analysis for Doripenem Regimens in Intensive Care Unit Patient"],"prefix":"10.1248","volume":"40","author":[{"given":"Ryota","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhki","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care, Faculty of Medicine, Oita University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihisa","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care, Faculty of Medicine, Oita University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Ohchi","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care, Faculty of Medicine, Oita University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamio","family":"Ueno","sequence":"additional","affiliation":[{"name":"Clinical Laboratory Center of Oita University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shusaku","family":"Kurogi","sequence":"additional","affiliation":[{"name":"Clinical Laboratory Center of Oita University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko","family":"Nonoshita","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Oita University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vivo<\/i> activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. Antimicrob. Agents Chemother.<\/i>, 52<\/b>, 761\u2013766 (2008).","DOI":"10.1128\/AAC.01128-07"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA. Comparative review of the carbapenems. Drugs<\/i>, 67<\/b>, 1027\u20131052 (2007).","DOI":"10.2165\/00003495-200767070-00006"},{"key":"3","unstructured":"3) Tsuji M, Furuya N, Matsumoto T, Ishii Y, Ohno A, Tateda K. In vitro<\/i> and in vivo<\/i> antibacterial activity of doripenem, a new carbapenem. Jpn. J. Chemother.<\/i>, 53<\/b>, 1\u201316 (2005)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Kim A, Banevicius MA, Nicolau DP. In vivo<\/i> pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures. Antimicrob. Agents Chemother.<\/i>, 52<\/b>, 2497\u20132502 (2008).","DOI":"10.1128\/AAC.01252-07"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit. Care Med.<\/i>, 31<\/b>, 2742\u20132751 (2003).","DOI":"10.1097\/01.CCM.0000098031.24329.10"},{"key":"6","unstructured":"6) Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Crit. Care Med.<\/i>, 41<\/b>, 580\u2013637 (2013)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am. J. Med.<\/i>, 115<\/b>, 529\u2013535 (2003).","DOI":"10.1016\/j.amjmed.2003.07.005"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Roberts JA, Lipman J. Pharmacokinetic issue for antibiotics in the critically ill patient. Crit. Care Med.<\/i>, 37<\/b>, 840\u2013851, quiz, 859 (2009).","DOI":"10.1097\/CCM.0b013e3181961bff"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit. Care Med.<\/i>, 29<\/b> (Suppl), S99\u2013S106 (2001).","DOI":"10.1097\/00003246-200107001-00032"},{"key":"10","unstructured":"10) Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: Implications for antibacterial dosing in the critically ill. Clin. Pharmacokinet.<\/i>, 49<\/b>, 1\u201316 (2010)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Cirillo I, Mannens G, Janssen C, Vermeir M, Cuyckens F, Desai-Krieger D, Vaccaro N, Kao LM, Devineni D, Redman R, Turner K. Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. Antimicrob. Agents Chemother.<\/i>, 52<\/b>, 3478\u20133483 (2008).","DOI":"10.1128\/AAC.00424-08"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Ikawa K, Morikawa N, Uehara S, Monden K, Yamada Y, Honda N, Kumon H. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients. Int. J. Antimicrob. Agents<\/i>, 33<\/b>, 276\u2013279 (2009).","DOI":"10.1016\/j.ijantimicag.2008.08.031"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Ikeda K, Ikawa K, Morikawa N, Kameda K, Urakawa N, Ohge H, Sueda T. Quantification of doripenem in human plasma and peritoneal fluid by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.<\/i>, 867<\/b>, 20\u201325 (2008).","DOI":"10.1016\/j.jchromb.2008.03.001"},{"key":"14","unstructured":"14) Hori T, Nakano M, Kimura Y, Murakami K. Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals. In Vivo<\/i>, 20<\/b>, 91\u201396 (2006)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Nandy P, Samtani MN, Lin R. Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients. Antimicrob. Agents Chemother.<\/i>, 54<\/b>, 2354\u20132359 (2010).","DOI":"10.1128\/AAC.01649-09"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron<\/i>, 16<\/b>, 31\u201341 (1976).","DOI":"10.1159\/000180580"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Yamaoka K, Nakagawa T, Tanaka H, Yasuhara M, Okumura K, Hori R. A nonlinear multiple regression program, MULTI2 (BAYES), based on Bayesian algorithm for microcomputers. J. Pharmacobiodyn.<\/i>, 8<\/b>, 246\u2013256 (1985).","DOI":"10.1248\/bpb1978.8.246"},{"key":"18","unstructured":"18) Finibax Japanese package insert."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Nalda-Molina R, Dokoumetzidis A, Charkoftaki G, Dimaraki E, Margetis K, Archontaki H, Markantonis S, Boutos N, Sakas D, Vryonis E, Skoutelis A, Valsami G. Pharmacokinetics of doripenem in CSF of patients with non-inflamed meninges. J. Antimicrob. Chemother.<\/i>, 67<\/b>, 1722\u20131729 (2012).","DOI":"10.1093\/jac\/dks106"},{"key":"20","unstructured":"20) Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin. Microbiol. Infect.<\/i>, 11<\/b>, 974\u2013984 (2005)."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Matsuo Y, Ishibashi T, Kubota R, Wajima T. Population pharmacokinetics of doripenem in Japanese subjects and Monte-Carlo simulation for patients with renal impairment. J. Infect. Chemother.<\/i>, 21<\/b>, 123\u2013129 (2015).","DOI":"10.1016\/j.jiac.2014.10.014"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Roberts JA, Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit. Care Med.<\/i>, 41<\/b>, 489\u2013495 (2013).","DOI":"10.1097\/CCM.0b013e31826ab4c4"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Kunzendorf U, Haase M, Rolver L, Haase-Fielitz A. Novel aspects of pharmacological therapies for acute renal failure. Drugs<\/i>, 70<\/b>, 1099\u20131114 (2010).","DOI":"10.2165\/11535890-000000000-00000"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Martin JH, Fay MF, Udy A, Roberts J, Kirkpatrick C, Ungerer J, Lipman J. Pitfalls of using estimations of glomerular filtration rate in an intensive care population. Intern. Med. J.<\/i>, 41<\/b>, 537\u2013543 (2011).","DOI":"10.1111\/j.1445-5994.2009.02160.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Sagheb MM, Namazi S, Geramizadeh B, Karimzadeh A, Oghazian MB, Karimzadeh I. Serum cystatin C as a marker of renal function in critically ill patients with normal serum creatinine. Nephrourol. Mon.<\/i>, 6<\/b>, e15224 (2014).","DOI":"10.5812\/numonthly.15224"},{"key":"26","unstructured":"26) Frazee EN, Rule AD, Herrmann SM, Kashani KB, Leung N, Virk A, Voskoboev N, Lieske JC. Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study. Crit. Care<\/i>, 18<\/b>, R110 (2014)."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Suzuki A, Imanishi Y, Nakano S, Niwa T, Ohmori T, Shirai K, Yoshida S, Furuta N, Takemura M, Ito H, Ieiri I, Seishima M, Ogura S, Itoh Y. Usefulness of serum cystatin C to determine the dose of vancomycin in critically ill patients. J. Pharm. Pharmacol.<\/i>, 62<\/b>, 901\u2013907 (2010).","DOI":"10.1211\/jpp.62.07.0011"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Abdul-Aziz MH, Abd Rahman AN, Mat-Nor MB, Sulaiman H, Wallis SC, Lipman J, Roberts JA, Staatz CE. Population pharmacokinetics of doripenem in critically ill patients with sepsis in a Malaysian intensive care unit. Antimicrob. Agents Chemother.<\/i>, 60<\/b>, 206\u2013214 (2015).","DOI":"10.1128\/AAC.01543-15"}],"container-title":["Biological & Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/8\/40_b17-00008\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T17:31:28Z","timestamp":1569951088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/40\/8\/40_b17-00008\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b17-00008","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}